TY - JOUR
T1 - Children with Near-Fatal Asthma
T2 - The Use of Inhaled Volatile Anesthetics and Extracorporeal Membrane Oxygenation
AU - Custer, Chasity M.
AU - O'neil, Erika R.
AU - Paskaradevan, Janaki
AU - Rissmiller, Brian J.
AU - Gazzaneo, Maria C.
N1 - Publisher Copyright:
© 2022, Mary Ann Liebert, Inc., publishers 2022.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Background and Purpose: The use of extracorporeal membrane oxygenation (ECMO) has been described for near-fatal asthma that continues to be refractory despite maximal medical therapy. Methods: Patients admitted to the pediatric intensive care unit at Texas Children's Hospital from 2012 to 2020 with the diagnosis of asthma who were supported on ECMO or isoflurane were included in the study. Patient demographics, medication usage, and complications were compared between the case group (ECMO, n = 12) and the control group (isoflurane only, n = 8). Results: All patients survived to discharge. ECMO patients received shorter durations of albuterol (12 versus 104 h, P = 0.0002) and terbutaline (13.3 versus 31.5 h, P = 0.0250). There were no differences in complication rates between the 2 groups. Conclusion: ECMO is a reasonable and safe support method for patients with near-fatal asthma and may lead to less bronchodilator medication exposure when compared with inhaled volatile anesthetic use.
AB - Background and Purpose: The use of extracorporeal membrane oxygenation (ECMO) has been described for near-fatal asthma that continues to be refractory despite maximal medical therapy. Methods: Patients admitted to the pediatric intensive care unit at Texas Children's Hospital from 2012 to 2020 with the diagnosis of asthma who were supported on ECMO or isoflurane were included in the study. Patient demographics, medication usage, and complications were compared between the case group (ECMO, n = 12) and the control group (isoflurane only, n = 8). Results: All patients survived to discharge. ECMO patients received shorter durations of albuterol (12 versus 104 h, P = 0.0002) and terbutaline (13.3 versus 31.5 h, P = 0.0250). There were no differences in complication rates between the 2 groups. Conclusion: ECMO is a reasonable and safe support method for patients with near-fatal asthma and may lead to less bronchodilator medication exposure when compared with inhaled volatile anesthetic use.
KW - extracorporeal membrane oxygenation
KW - intensive care units
KW - pediatric
KW - social determinants of health
KW - status asthmaticus
UR - http://www.scopus.com/inward/record.url?scp=85144328592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144328592&partnerID=8YFLogxK
U2 - 10.1089/ped.2022.0126
DO - 10.1089/ped.2022.0126
M3 - Article
C2 - 36537704
AN - SCOPUS:85144328592
SN - 2151-321X
VL - 35
SP - 170
EP - 173
JO - Pediatric, Allergy, Immunology, and Pulmonology
JF - Pediatric, Allergy, Immunology, and Pulmonology
IS - 4
ER -
